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Latency of Epstein-Barr virus infection may be generated 
by surviving immortalized B cells or by continuous re-infec- 
tion. EBV-positive B-cell tumors have been found following 
bone-marrow transplantation (BMT) and were of donor type 
in the few cases investigated. We established a B-cell line from 
the bone marrow of a patient in complete remission following 
allogeneic BMT for aplastic anemia 18 months post-grafting. 
Differences in sex and isoenzymes allowed an exact determi- 
nation of chimerism in our case. While the patient showed 
persistent complete chimerism of all cell lineages, cells grown 
in culture were of recipient type. They expressed B-cell mark- 
ers, showed a monoclonal rearrangement of the immunoglob- 
ulin genes and carried EBV-associated antigens. As direct 
preparations of cells from the patient did not contain detect- 
able recipient-type cells, it appeared likely that small numbers 
of EBV-transformed B cells of the recipient survived for long 
periods in this patient. For the development of secondary B- 
cell neoplasms in vivo, additional patho-physiological steps 
like severe graft versus host disease or T-cell suppression are 
obviously required because the patient was still free of lyrn- 
phoma 3 years post-grafting. 
Epstein-Barr virus infection can lead in vivo to immortalized 
B-cell clones which are suppressed by T-cell-mediated immu- 
nity (Rickinson et al., 1981). It is an open question whether 
the persistence of such B cells in vivo is the result of continu- 
ous re-infection by virus shedding from saliva (Wolf et al., 
1984; Yao et al., 1985a) or of survival of low numbers of 
infected B cells (Yao et al., 198%). Lymphoproliferative tu- 
mors do not usually carry EBV genomes (Andiman et al., 
1983) but a few cases of EBV-positive lymphoma have been 
described following BMT (Schubach et al., 1985). These were 
monoclonal (Schubach et al., 1982), but polyclonal tumors 
have been described as well and all were of donor origin 
whenever this point was investigated (Martin et al., 1984). 
This, together with the observation that EBV-specific cyto- 
toxic T cells re-emerge relatively early after allogeneic BMT 
(Crawford et a l . ,  1986) argues against long-term persistence 
of infected B cells in vivo. 
Allogeneic BMT offers an opportunity to study this problem 
since either sex differences between donor and recipient or 
genetic polymorphism of cellular isoenzymes such as AcP or 
PGM-1 make it possible, in most cases, to determine whether 
the cells in BMT patients are of donor or recipient origin 
(Mittermuller et a l . ,  1986). More than 90% of European adults 
have been infected with EBV (Yao et al., 1985~).  It is an open 
question whether EBV-immortalized B-cell clones of the re- 
cipient persist or whether they are eliminated either by BMT 
conditioning or by immunological mechanisms. We report 
findings which suggest that EBV-transformed clones of recip- 
ient origin can indeed persist after BMT even if the patient has 
become a “complete chimera” according to the most sensitive 
criteria that are presently available. 
Patient 
A 43-year-old woman presented with severe tricytopenia 
following nitrefazol (anti-obesity drug) complicated by bleed- 
PATIENT AND METHODS 
ing episodes and septic complications in June 1984. A diag- 
nosis of severe aplastic anemia was confirmed by bone-marrow 
biopsy and in August 1984 the patient was prepared for allo- 
geneic BMT by cyclophosphamide i .v.  (40 mg/kg body weight 
days -5 to -2 )  plus total nodal irradiation (7 Gy, day -1). She 
received 4 x lo8 nucleated cells per kg body weight from 
her HLA-identical MLC-unreactive brother and recovered 
promptly with a leukocyte count of > 1 X 109/1 on day 17. 
Post-grafting immunosuppression consisted of Cyclosporin A 
i.v. 5 mg/kg body weight for 5 days followed by 3 mg/kg 
until day 34 and subsequently orally until day 250 (9 months). 
No  steroids were given at any time. At the time of writing, 
she is in full clinical remission (40 months). 
Cell preparation 
The patient’s bone marrow cells were aspirated with preser- 
vative-free heparin after informed consent had been obtained. 
For culture and cytogenetic studies the cells were centrifuged 
over Ficoll (density 1,077 g/l). For enzyme analyses the eryth- 
rocytes were sedimented and the leukocyte-rich buffy coat was 
further processed. Polymorphonuclear cells were isolated from 
the pellet of Ficoll separations by lysis of the contaminating 
erythrocytes with ammonium chloride. Thrombocytes were 
recovered from the upper layers of the buffy coat after mild 
sedimentation. T cells and monocytes were isolated in the 
pellet of Ficoll-gradients by a direct immune-rosetting tech- 
nique (Wilhelm et a l . ,  1986) using erythrocytes coated with 
pan-T-antibodies (CD2, Rieber et al., 1986) or with anti- 
monocyte antibodies. T-depleted lymphocytes were recovered 
from the interface. 
Morphological studies 
Smears were prepared by standard methods employing May- 
Griinwald-Giernsa stain, periodic acid Schiff reaction and 
myeloperoxidase. 
Immunological phenotyping 
Surface markers were identified with an enzyme-immunoas- 
say on poly-1-lysine coated adhesive slides (Morich et a l . ,  
1983) employing polyvalent alkaline phosphatase (Sigma)-con- 
jugated goat-anti-mouse immunoglobulin. The color reaction 
was performed with 0.1 % naphthol-AS-MX-phosphate (Sigma) 
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TABLE I - PHENOTYPE OF BMT-CHIMERA-DERIVED CELL LINE 
B-1 (CD20) B-2 (CD19) anti-IgM -1gG -1gD -kappa -lambda 
% positive 90 50 30 0 0 70 0 
% positive 50 50 0 0 0 0 0 
15 (CDIO) OKT-9 VIM-DJ (CD15) VIM-2 OKM-I (CD14) My4 My7 
673 
plus 2 % dimethylformamide (Merck), 0.1 % fast red (Serva, 
Heidelberg, FRG) and 0.024% levamisole in 0.1 molar Tris- 
buffer. Each slide contained a control without primary anti- 
body. The MAbs used were VIM-DS and VIM-2 (CD15) 
which are directed against myeloid differentiation antigens, 
kindly provided by Dr. W. Knapp, Vienna, B-1 and B-2 
(CD20, CD19) which are found on B cells and their progeni- 
tors, anti-human IgG, -IgM, anti-kappa and anti-lambda light 
chain antibodies as well as J5 (anti-common acute lymphoblas- 
tic leukemia antibody, characteristic for immature lymphoid 
cells) (CDlO), which were purchased from Coulter, Hialeah, 
FL, OKT-3 (CD3) and OKT-9 (which detects the transferrin 
receptor) from Ortho, Raritan, NJ. The CD-classification has 
been reviewed recently (Foon and Todd, 1986). 
Cultures 
Suspension cultures were initiated in 30-ml flasks with 
2 . 5 ~  lo6 MNC in 5 ml Iscove-modified Dulbecco’s medium 
supplemented with 10% fetal calf serum, 10% horse serum 
(both by HyClone, Logan, UT) and 5% of a supernatant of 
the 5637 cell line which contains G-CSF among other factors 
and stimulates the growth of myeloid and erythroid progenitor 
cells (Gerhartz and Wilmanns, 1986). All cultures were incu- 
bated at 37°C and 5% C02  in a fully humidified atmosphere 
and were re-fed weekly with 2.5 ml medium plus supplemenls. 
Cvtogenetirs 
Giemsa-banding techniques (Seabright, 1971). 
Karyotypic analyses were performed according to standard 
Enzyrne analvsis 
After washing the cells with isotonic saline, freezing and 
thawing and ultrasonic treatment, the debris-free supernatant 
was analyzed. Unprocessed hair roots were typed after pre- 
incubation with Triton X 100 for 20 min (Mittermuller et a l . ,  
1984). PGM-1 isoenzynie analysis was performed by ultra- 
thin isoelectric focusing on polyacrylamide gels (size 
2 4 0 ~  1 2 0 ~ 0 . 2 4  mm, PH 5-6.5) (Mittermiiller et al . ,  1985). 
AcP isoenzymes were determined by ultra-thin-layer isoelec- 
tric focusing in polyacrylamide gels (Burdet and Whitehead, 
1977) with modifications (size 2 4 0 ~  120X0.24 mm, PH 3.5- 
9.5). 
Western blots 
EBNA was demonstrated by Western blot analysis (Motz et 
al . ,  1986). Briefly, cell lysates were separated by SDS-poly- 
acrylamide gel electrophoresis, transferred onto nitrocellulose 
filters and incubated overnight with a 1:50 diluted serum pool. 
Bound antibodies were detected by peroxidase-conjugated anti- 
human-IgG antibodies (Ortho), stained with 0.1 % H202 and 
0.5 m g h l  diaminobenzidine. 
DNA anulysis 
DNA was extracted from cultured cells by standard tech- 
niques (Maniatis et a l . ,  1982). Fifteen micrograms of DNA 
were digested with appropriate restriction enzymes (Boerin- 
ger, Mannheim, FRG), electrophoresed on a 0.7% agarose 
gel, blotted and hybridized (Raghavachar et a l . ,  1986). To 
demonstrate Ig-gene rearrangements, Hind I11 digests were 
hybridized to a 1.3-kb Eco RI Cp probe which detects a 17-kb 
germline band (Bakhshi et al . ,  1983) and from Bam HI digests 
to a c-kappa probe which detects a 12-kb germline band (Bakh- 
shi et al., 1983). Both probes were kindly provided by Dr. P. 
Leder. After hybridization, the filters were washed under 
stringent conditions and exposed to XAR-5 film (Kodak) using 
Dupont Lightning-Plus intensifying screens for up to 24 hr at 
-70°C. 
RESULTS 
Cell line 
Suspension cultures of the patient’s bone-marrow cells were 
set up 18 months post-grafting. The possibility that the culture 
supernatant of the 5637 cell line which was used for initial 
stimulation contained EBV was ruled out by previous exper- 
iments in which human cord-blood cells failed to grow contin- 
uously with this stimulator. The patient’s cells decreased in 
number during the first 6 weeks of culture but thereafter 
increased continuously to about 1OX lo6 MNC per flask per 
week. The cells within the cultures were morphologically 
undifferentiated. They were negative for peroxidase and a 
minority of about 2 %  was positive for periodic acid Schiff 
reaction (data not shown). 
Immune phenotyping 
Table I shows that the cells expressed B markers (CD19, 
CD20, CDlO) with surface IgM and kappa light chains, but 
no T-cell or myeloid markers. 
EBV analysis 
The cells were positive for EBNA and VCA at the surface. 
Moreover, in a Western blot analysis of cell lysates, EBNA 
was clearly shown as a typical band (gel not shown). This 
finding supported the view that the cells in culture were im- 
mortalized by EBV. 
DNA analysis 
Surface marker analysis suggested that the cells were mono- 
clonal. This was confirmed by Southern blot analysis of DNA 
extracted from the cell line (Fig. 1). Hybridization to p -  and 
kappa-specific probes clearly demonstrated a monoclonal bial- 
lelic rearrangement of both genes with no residual germ-line 
bands. 
Cytogenetic analysis 
In direct preparations of bone-marrow cells taken from the 
patient 11 and 19 months post-grafting, 25 and 27 metaphases 
were analyzed, respectively, all of which were male (Fig. 2a). 
Surprisingly, cells of the cultured line all had a female karyo- 
type (Fig. 2b). The cell line, therefore, must have been de- 
rived from the recipients’ B cells. This finding prompted a 
more detailed determination of the chimeric state using isoen- 
zyme analyses. 
Acid phosphatase typing (Fig. 3) 
Figure 3 shows the results of AcP typing for all the different 
purified cell preparations. The recipient was heterozygous BA 
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FIGURE 1 - Southern blot analysis of Ig genes. DNA of the cell line 
was digested with Hind 111 and Barn HI, electrophoresed, blotted and 
hybridized to a cp (a)  and a c-kappa probe (b) .  The 2 bands indicate a 
monoclonal biallelic rearrangement. 
for AcP, showing the 3 main bands in isoelectric focusing of 
her hair root cells. The donor had the phenotype B comprising 
the 2 main bands on the gel. Following BMT all the different 
cell populations-erythrocytes, platelets, polymorphonuclear 
leukocytes, T lymphocytes, T-depleted lymphocytes, mono- 
cytes, total sedimented bone-marrow cells as well as Ficoll- 
isolated MNC-showed the B-type bands only (Fig. 3). In 
contrast, the cultured cells had 3 bands, thus demonstrating 
the presence of the recipient type A. However, a sub-popula- 
tion of type-B cells could not be excluded. Therefore, corre- 
sponding investigations were made by phosphoglucomutase- 1- 
isoenzymes. 
Phosphoglucomutase- I typing (Fig. 4) 
Four alleles of PGM-1 exist (a1 to a4). The patient was 
homozygous a1 as demonstrated by analysis of her hair root 
cells (erythrocytes contaminated with a2 and a3 bands via 
transfusions, Fig. 4). The donor cells were heterozygous a l l  
a3. Following BMT, all cell lineages showed the heterozygous 
bands alla3, implying presence of donor-type cells. In con- 
trast, the cultured cells showed the a1 band only, thus proving 
unequivocally that the cell line was of recipient origin. 
DISCUSSION 
Most adult individuals show immunity to EBV. The level of 
virus-infected B cells in the blood has been shown to corre- 
spond to the level of EBV-shedding from the throat of healthy 
seropositive individuals (Wolf et al . ,  1984; Yao et al . ,  1985~). 
This, together with similar observations in immunosuppressed 
patients, supports the hypothesis that the EBV carrier state 
represents a chronic infection rather than a reactivation of 
“latent” EBV-immortalized clones (Yao et a l . ,  198%; Mod- 
row et al., 1987). Allogeneic BMT offers an excellent oppor- 
tunity to study these problems for several reasons, e.g., (a) 
allogeneic BMT chimeras often have markers which make it 
possible to determine whether the cells originate from donor 
or host; (b) they are, temporarily, heavily immunosuppressed 
and might therefore be more susceptible to reactivation of 
EBV-induced diseases. 
However, the conditioning regimen of BMT might not only 
destroy the patient’s own hemopoietic cells but also eliminate 
B cells which have been immortalized by EBV. In fact, the 
development of secondary EBV-positive B-cell lymphomas 
has been only rarely observed and all cases have been of donor 
origin, whenever this was investigated (Schubach et al . ,  1982; 
Martin et al., 1984). 
In our case, both the recipient and the donor were sero- 
positive for EBV but did not exhibit any clinical or serological 
signs of reactivated infection. Nevertheless, an EBV-positive 
B-cell line could be grown 18 months post-grafting when the 
patient was off any immunosuppressive therapy and with no 
signs of GvHD. Differences in sex as well as in AcP and 
PGM-1 isoenzymes between donor and recipient enabled us to 
investigate the chimeric state of the transplanted patient in 
detail. Cytogenetic analysis may fail to identify 510% of 
different cells, but the isoenzyme methodology is independent 
of cell proliferation and can detect a proportion of only 1% 
foreign cells (Mittermuller et al . ,  1986). It has been repeatedly 
shown, by both methods, that our patient was a complete 
FIGURE 2 - Kuryotypic analysis. Uncultured cells of  the patient’s bone marrow had a male karyotype ( a ) ,  while that of the cell line was female 
(b) .
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FIGURE 3 - Acid phosphatase typing. AcP isoenzymes were deter- 
mined by isoelectric focusing. Each lane shows the bands of a differ- 
ent specimen: erythrocytes (E) of patient and donor before BMT. hair- 
root cells of patient (HRC). erythrocytes of patient after BMT (E), as 
well as her platelets (PI), polymorphonuclear leukocytes (PMN), T- 
lymphocytes (TL), T-depleted lymphocytes (TdL), monocytes (M), 
total sedimented BM-cells (BMSC), and Ficoll-separated BM cells 
(BM-MNC). The last lane shows the cell line (CC). 
chimera with no detectable residual host-type cells in any of 
the different cell lineages (Figs. 2a, 3 and 4). 
The cell line, however, was clearly of recipient origin (Figs. 
2b, 3 and 4). Detailed analysis showed that it was an EBV- 
positive B cell line. The possibility that the recipient-type 
EBV-positive cell line was a result of in vivo re-infection post- 
grafting cannot be entirely ruled out because the sensitivity of 
the method of determining the chimeric state does not exceed 
1 % . Nevertheless, the vast excess of donor type-B cells makes 
it more likely that this cell line had originated from B cells 
which had been infected before BMT. This suggests that EBV- 
immortalized B cells may survive for longer periods in the 
human organism. Moreover, the detection of such EBV-im- 
mortalized cells shows that they may survive the conditioning 
regimen (high-dose cyclophosphamide plus total lymph-node 
irradiation). 
The cell line was clearly monoclonal, as confirmed by sur- 
face markers and DNA analysis (Table I ,  Fig. 1). This does 
not necessarily indicate monoclonality in vivo since it may 
have been established by in vitro selection. 
FIGURE 4 - Phospkoglucomutase-1 analysis. PGM-1 isoenzymes 
were detected by isoelectric focusing. Each lane presents a different 
specimen which follows the sequence given in Figure 3. 
The contribution of the 5637-conditioned medium to the 
outgrowth of the cell line is unclear. Since factors produced 
by the cell line do not support growth of lymphoid cells (Myers 
er al.,  1984), these might have acted-if influencing growth of 
the cell line at all-via stimulation of accessory cells. 
Our findings suggest that recipient-derived EBV-immortal- 
ized B cells persist after allogeneic BMT in patients who 
appear to be “complete chimeras” even when the most sensi- 
tive methods presently available are used. One may speculate 
that such cells could give rise to secondary B-cell lymphomas 
under certain circumstances. However, our patient did not 
develop lymphoma within the 3 years following grafting. 
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